IP20: Bladder Cancer: Non-invasive II
Friday, May 15, 2026 3:30 PM to 5:30 PM · 2 hr. (America/New_York)
146A
Poster and Podium Sessions
Oncology: Bladder
Friday, May 15
IP20-01: Preoperative Angioembolization Followed by Transurethral Resection of Bladder Tumor for Large Bladder Tumors: Early Clinical Experiences
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-02: BCG-rechallenge after treatment failure: long-term outcomes from a multi-institutional cohort
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-03: Real-World Outcomes of Bladder-Sparing Strategies for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Multicenter Study
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-04: First Results from CORE-008 Cohort CX- Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-05: Real-World Adherence to EAU-Recommended Non-Muscle-Invasive Bladder Cancer Management: from Evidence-Based Practice to Oncological Outcomes
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-06: Thermo-sensitive Hydrogel System Enables Sustained Intravesical Delivery of Antibody–Drug Conjugates for Effective Treatment of Non–Muscle-Invasive Bladder Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-07: Improved Outcomes in High-Risk Non-Muscle Invasive Bladder Cancer with Oral 5- Aminolevulinic Acid Fluorescence Cystoscopy–Assisted Transurethral Resection of Bladder Tumors
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-08: Patient time toxicity from management options for non-muscle invasive bladder cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-09: Circulating tumor DNA as a biomarker for upstaging and adverse pathology in high-risk non–muscle-invasive bladder cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-10: Final results from a phase I clinical trial of intravesical therapy with autologous tumor infiltrating lymphocytes (TIL) in BCG-exposed non-muscle invasive bladder cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-11: Intravesical Bacillus Calmette-Guerin (BCG) and Gemcitabine Induces a Distinct Urinary Cytokine Profile Marked by Enhanced Immune Cell Trafficking and Reduced Immunosuppression
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-12: Association of a Computational Histology AI (CHAI) Prognostic Biomarker with High Grade Recurrence Independent of Traditional Risk Factors in Low Grade Non-Muscle Invasive Bladder Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-13: ADVANCED-2 (Cohort B): Interim Efficacy and Safety Data in BCG-Unresponsive Participants With High-Grade Non-Muscle Invasive Bladder Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-14: Assessment of Disease Recurrence in Complete Responders after Stopping Sequential Gemcitabine and Docetaxel in patients with High-Risk non-muscle invasive bladder cancer.
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
Kenneth Richer · Ross University School Of Medicine
IP20-15: Phase-2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)-Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3 Year Outcomes
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-16: Extravesical Recurrence in Patients with Ta/T1 Bladder Cancer and Carcinoma In Situ: Results from a Large Single-Center Cohort
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-17: Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-18: Similar long-term efficacy of reduced-dose induction BCG compared to full-dose induction BCG in the treatment of intermediate- and high-risk non-muscle invasive bladder cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-19: EGCG-Cu@BCG Synergistically Treats Bladder Cancer by Inducing Immunogenic Cell Death
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
hailong zhang
IP20-20: Prospective Validation of BIAS and IBCG Scoring Systems for Predicting High-Grade Progression in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer initially Eligible for Active Surveillance
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-21: Baseline T-Cell Exhaustion Predicts BCG Failure in High-Risk Non-Muscle Invasive Bladder Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-22: Impact of Tumor Location on preoperative outcomes in En Bloc Resection of Bladder Tumors: A Multicenter Japan En bloc TUR (JET) Study
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-23: Spectrum of BCG-Related Adverse Events Predicts Oncologic Outcomes in Non–Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-24: Blue Light Cystoscopy Enables Earlier CIS Recognition and Can Guide Risk-Appropriate Management of High-Risk Non–Muscle-Invasive Bladder Cancer: Real-World Outcomes from a U.S. Claims Cohort
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-25: Germline DNA repair gene (gDRG) variants in BCG un-responsive patients: a potential genetic implications for risk stratification and target therapy
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-26: Oncologic Outcomes of Maintenance BCG versus Maintenance Gemcitabine/Docetaxel After Induction BCG for Non-Muscle-Invasive Bladder Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-27: Longitudinal Assessment of Patient-Reported Quality of Life and Mental Health During Active Surveillance for Low-Grade NMIBC
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-28: Freedom from Bladder Cancer: Time-to-Event Reporting in CIS+ BCG-Unresponsive Trials
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-29: The Association of Delay to BCG Administration Following TURBT and Oncologic Outcomes
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
IP20-30: Prophylactic Ureteral Stenting Prevents Clinically Significant Stricture Formation Following Ureteral Orifice Resection During TURBT: A Risk-Stratified Analysis
Friday, May 15, 2026 3:30 PM to 5:30 PM
146A
